Biologics

Bone Therapeutics SA and Asahi Kasei sign exclusive license agreement for PREOB® in Japan
Biologics Top Stories

Bone Therapeutics SA and Asahi Kasei sign exclusive license agreement for PREOB® in Japan

Gosselies, Belgium, 22 September 2017, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces it has signed an exclusive, royalty-bearing license agreement with one of Japan’s leading industrial companies, Asahi Kasei Corporation (Tokyo: […]

BONESUPPORT™ Data Presented at EORS Highlights Cerament® Bone Void Filler’s Ability to Elute Drugs With Potential to Enhance Bone Growth
Biologics

BONESUPPORT™ Data Presented at EORS Highlights Cerament® Bone Void Filler’s Ability to Elute Drugs With Potential to Enhance Bone Growth

20-Sep-2017 Lund, Sweden, 08.00 CEST, 20 September 2017 – BONESUPPORT an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT platform announces that a pre-clinical  study evaluating the in-vivo release kinetics of radio-labelled […]

Bone Therapeutics SA : Announces all Patients Meet Primary Endpoint in ALLOB® Phase I/IIA Delayed-Union Study Interim Analysis
Biologics

Bone Therapeutics SA : Announces all Patients Meet Primary Endpoint in ALLOB® Phase I/IIA Delayed-Union Study Interim Analysis

Gosselies, Belgium, 20 September 2017, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces positive interim efficacy results in the Phase I/IIA delayed-union study of its allogeneic bone cell therapy product ALLOB® in 16 […]

Biogennix Bone Graft Substitute Materials Used to Treat 6000th Patient
Biologics

Biogennix Bone Graft Substitute Materials Used to Treat 6000th Patient

September 20, 2017 IRVINE, Calif.–(BUSINESS WIRE)–Irvine, California-based Biogennix, an osteobiologic company which develops, manufactures, and distributes proprietary bone graft substitutes used for bone fusion procedures, announced today that its products have now been used in more than 6000 patients. The company’s novel bone graft substitutes, osteoSPAN™ and Morpheus™ are resorbable, […]

Bone Solutions Inc. Launches OsteoCrete® Magnesium-Based Bone Void Filler
Biologics Top Stories

Bone Solutions Inc. Launches OsteoCrete® Magnesium-Based Bone Void Filler

(PRWEB) SEPTEMBER 19, 2017 Bone Solutions Inc. (BSI), an orthobiologics technology company located in Colleyville, TX, announces the launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone void filler is designed to assist with bone repair and generation, and it’s the first in the U.S. to incorporate magnesium, a critical […]

Organogenesis Names New Chief Commercial Officer and Chief Operating Officer
Biologics Top Stories

Organogenesis Names New Chief Commercial Officer and Chief Operating Officer

CANTON, Mass., Sept. 19, 2017 /PRNewswire/ — Organogenesis Inc., a commercial leader in the field of regenerative medicine with a portfolio of advanced and next-generation bioactive and acellular biomaterials products in the advanced wound care and surgical biologics markets, has elevated two industry veterans and longtime company employees, Brian Grow and Patrick Bilbo, to Chief Commercial […]

MiMedx To Host Shareholder Call On September 21, 2017 To Update Progress On Various Strategic Initiatives And Respond To Topics Requested By Shareholders
Biologics Financial

MiMedx To Host Shareholder Call On September 21, 2017 To Update Progress On Various Strategic Initiatives And Respond To Topics Requested By Shareholders

MARIETTA, Ga., Sept. 19, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today it will be hosting a webcast on Thursday, September 21, 2017 beginning at 10:30 a.m. Eastern Time to […]

MiMedx Files With The FDA To Initiate The Company’s Investigational New Drug Phase 2 Clinical Trial For Osteoarthritis Of The Knee
Biologics Regulatory Top Stories

MiMedx Files With The FDA To Initiate The Company’s Investigational New Drug Phase 2 Clinical Trial For Osteoarthritis Of The Knee

MARIETTA, Ga., Sept. 19, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that the Company has filed with the Food and Drug Administration (FDA) to initiate its […]

RTI Surgical® Continues to Augment Leadership Team to Accelerate its Strategic Direction
Biologics

RTI Surgical® Continues to Augment Leadership Team to Accelerate its Strategic Direction

September 18, 2017/Roxane Wergin, Director, Corporate Communications ALACHUA, Fla. (September 18, 2017) – RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a leading global surgical implant company, announced today three new appointments to its senior leadership team to accelerate the Company’s strategic growth initiatives. They include Jonathon Singer, a member of RTI’s board of directors, […]

Bioventus Announces First Patients Enrolled in BONES Study for EXOGEN®
Biologics Extremities

Bioventus Announces First Patients Enrolled in BONES Study for EXOGEN®

September 13, 2017 DURHAM, N.C.–(BUSINESS WIRE)–Bioventus, a global leader in orthobiologics, today announced the first patients have been enrolled in its BONES (Bioventus Observational Non-interventional EXOGEN Studies) clinical development program. BONES includes three observational, non-interventional, direct-to-patient studies designed to collect real world data on the use of the EXOGEN Ultrasound Bone Healing System. EXOGEN uses […]

MiMedx Recognized as Number 5 on Fortune Magazine’s List of the 100 Fastest Growing Public Companies
Biologics Top Stories

MiMedx Recognized as Number 5 on Fortune Magazine’s List of the 100 Fastest Growing Public Companies

MARIETTA, Ga., Sept. 12, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that the Company has been recognized by Fortune Magazine as the fifth ranked company in Fortune’s 2017 list of […]

Cerapedics Announces Publication of Two-Year IDE Study Follow-Up Data on i-FACTOR™ Bone Graft in the Cervical Spine
Biologics

Cerapedics Announces Publication of Two-Year IDE Study Follow-Up Data on i-FACTOR™ Bone Graft in the Cervical Spine

WESTMINSTER, Colo., Sept. 12, 2017 /PRNewswire/ — Cerapedics, a privately-held orthobiologics company, today announced the publication of two-year follow-up data from an FDA Investigational Device Exemption (IDE) clinical trial of i-FACTOR™ Peptide Enhanced Bone Graft. The results published in the peer reviewed journal Neurosurgery show i-FACTOR Bone Graft is statistically superior in overall clinical success […]

$8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program
Biologics Top Stories

$8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program

HAIFA, Israel, Sept. 05, 2017 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that its Phase III study of PLX-PAD cells to support recovery following surgery for femoral neck fracture has been awarded an $8.7 million (7.4 million Euro) non-dilutive […]

Bioventus Receives US FDA Approval for DUROLANE®
Biologics Regulatory

Bioventus Receives US FDA Approval for DUROLANE®

September 05, 2017 DURHAM, N.C.–(BUSINESS WIRE)–Bioventus, a global leader in orthobiologic solutions, today announced it has received US FDA approval for DUROLANE, a single-injection, hyaluronic acid (HA) product used for joint lubrication in the treatment of pain associated with knee osteoarthritis (OA). Hyaluronic acid is a naturally occurring molecule that provides […]